Introduction: Congenital Hyperinsulinism (CHI) has not been previously studied in Ukraine. We therefore aimed to elucidate the genetics, clinical phenotype, histological subtype, treatment and ...

Credit: Sidra Medicine. Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism. The first pharmaceutical trial comes ...

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism. The first pharmaceutical trial comes after Sidra launched ...

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored Pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

This would be regarding the use of ersodetug in the ongoing phase 3 sunRIZE study targeting patients with Congenital Hyperinsulinism [cHI]. The reason investors should care about this trial before ...

Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market. For the second time ...